- Home
- CANF vs CTNT Comparison
CANF vs CTNT Comparison
Compare CANF & CTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CTNT
- Stock Information
- Founded
- CANF 1994
- CTNT 2016
- Country
- CANF Israel
- CTNT United States
- Employees
- CANF N/A
- CTNT N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CTNT
- Sector
- CANF Health Care
- CTNT
- Exchange
- CANF Nasdaq
- CTNT Nasdaq
- Market Cap
- CANF 9.4M
- CTNT 9.4M
- IPO Year
- CANF N/A
- CTNT 2023
- Fundamental
- Price
- CANF $1.81
- CTNT $1.97
- Analyst Decision
- CANF Strong Buy
- CTNT Hold
- Analyst Count
- CANF 2
- CTNT 1
- Target Price
- CANF $14.00
- CTNT N/A
- AVG Volume (30 Days)
- CANF 122.9K
- CTNT 41.2K
- Earning Date
- CANF 03-04-2025
- CTNT 03-17-2025
- Dividend Yield
- CANF N/A
- CTNT N/A
- EPS Growth
- CANF N/A
- CTNT N/A
- EPS
- CANF N/A
- CTNT N/A
- Revenue
- CANF $667,000.00
- CTNT $7,703,113.00
- Revenue This Year
- CANF $409.56
- CTNT N/A
- Revenue Next Year
- CANF N/A
- CTNT N/A
- P/E Ratio
- CANF N/A
- CTNT N/A
- Revenue Growth
- CANF N/A
- CTNT N/A
- 52 Week Low
- CANF $1.29
- CTNT $1.70
- 52 Week High
- CANF $4.69
- CTNT $236.16
- Technical
- Relative Strength Index (RSI)
- CANF 64.57
- CTNT 35.35
- Support Level
- CANF $1.45
- CTNT $1.86
- Resistance Level
- CANF $1.50
- CTNT $2.11
- Average True Range (ATR)
- CANF 0.12
- CTNT 0.11
- MACD
- CANF 0.05
- CTNT 0.02
- Stochastic Oscillator
- CANF 66.67
- CTNT 29.73
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a supplier of parallel-import vehicles sourced in the U.S. to be sold in the China market. The parallel-import vehicles refer to those purchased by dealers directly from overseas markets and imported for sale through channels other than brand manufacturers' official distribution systems. The company purchases automobiles, luxury brands such as Mercedes, BMW, Porsche, Lexus, and Bentley, from the U.S. market and resells them to customers, including both U.S. and PRC parallel-import car dealers. The company derives profits from the price difference between buying and selling prices for parallel-import vehicles.